Is Liptruzet still on the market?

Liptruzet: Status and Availability

Liptruzet, a fixed-dose combination of atorvastatin and ezetimibe, was approved by the FDA in June 2015 for the treatment of certain types of high cholesterol [1]. It was marketed by Merck.

Patent Expiration and Availability

According to DrugPatentWatch.com, the patent for Liptruzet was set to expire in June 2016 [2]. As of 2024, Liptruzet is no longer listed on the FDA's database as an available medication, suggesting it may have been discontinued or its availability severely restricted.

Generic Versions and Biosimilars

It's worth noting that generic versions of atorvastatin and ezetimibe, which are the individual active ingredients in Liptruzet, have been available for years. However, the fixed-dose combination of the two medications was only approved for a specific indication, which might impact the market for Liptruzet.

Competitor Landscape

The market for cholesterol-lowering medications is highly competitive, with several other options available, including generic atorvastatin and ezetimibe, as well as other fixed-dose combinations. The lack of information on Liptruzet's current status suggests that it may no longer be a commercially viable option.

Sources:
[1] FDA: Liptruzet Approved for Treatment of Certain Types of High Cholesterol (2015)
[2] DrugPatentWatch.com: Liptruzet Patent Expiration Date